Lipella Pharmaceuticals Valuation
| LIPO Stock | 0.19 0 0.53% |
Lipella Pharmaceuticals seems to be undervalued based on Macroaxis valuation methodology. Our model forecasts the value of Lipella Pharmaceuticals from analyzing the firm fundamentals such as Shares Outstanding of 4.62 M, return on equity of -2.48, and Operating Margin of (15.64) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lipella Pharmaceuticals' valuation include:
Price Book 0.5925 | Enterprise Value | Enterprise Value Ebitda (4.40) | Price Sales 2.9625 | Enterprise Value Revenue 0.1499 |
Undervalued
Today
Please note that Lipella Pharmaceuticals' price fluctuation is extremely dangerous at this time. Calculation of the real value of Lipella Pharmaceuticals is based on 3 months time horizon. Increasing Lipella Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lipella Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lipella Stock. However, Lipella Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.19 | Real 2.64 | Target 10.0 | Hype 0.19 |
The intrinsic value of Lipella Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lipella Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lipella Pharmaceuticals Common helps investors to forecast how Lipella stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lipella Pharmaceuticals more accurately as focusing exclusively on Lipella Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lipella Pharmaceuticals' intrinsic value based on its ongoing forecasts of Lipella Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lipella Pharmaceuticals' closest peers.
Lipella Pharmaceuticals Cash |
|
About Lipella Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Lipella Pharmaceuticals Common. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Lipella Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Lipella Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Lipella Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lipella Pharmaceuticals. We calculate exposure to Lipella Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lipella Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.8 M | -2.6 M | |
| Pretax Profit Margin | (10.76) | (11.29) | |
| Operating Profit Margin | (10.89) | (11.44) | |
| Net Loss | (10.76) | (11.29) | |
| Gross Profit Margin | (6.60) | (6.93) |
Lipella Pharmaceuticals Current Valuation Indicators
Lipella Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Lipella Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lipella Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lipella Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lipella Pharmaceuticals' worth.When determining whether Lipella Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipella Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipella Pharmaceuticals Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipella Pharmaceuticals Common Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Will Biotechnology sector continue expanding? Could Lipella diversify its offerings? Factors like these will boost the valuation of Lipella Pharmaceuticals. Expected growth trajectory for Lipella significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipella Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.33) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lipella Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipella Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lipella Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.